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ABSTRACT

Introduction: In 2006 it was estimated by the Substance Abuse and Mental Health
Service Administration (SAMHSA, 2007) that 19.9 million Americans used illicit drugs,
computing to roughly 8.0 % of the United States population. In 2007, there were 2.1
million active cocaine users, comprising 0.8 percent of the population. The National
Institute on Drug Abuse (NIDA) estimates that the total expenditure of drug-related
complications is greater than 500 billion dollars when healthcare, legal procedures and
job loss are considered. Research has shown that prolonged drug use has a profound
effect on the EEG recordings of drug addicts when compared to controls during cue
reactivity tests. Cue reactivity refers to a phenomenon in where individuals with a
history of drug abuse exhibit excessive psychophysiological responses to cues associated
with their drug of choice. The goal of this research is to develop gamma band EEG
indices to determine the effectiveness of neurofeedback therapies which are thought to
offer a non-invasive method of mediating EEG abnormalities resulting from prolonged
substance abuse.
Method: Ten current cocaine abusers were treated using neurofeedback protocol to
simultaneously increase SMR and decrease Theta activity, combined with Motivational
Interviewing sessions. Eight of them completed all planned pre and post-neurofeedback
cue reactivity tests with event-related EEG recording and clinical evaluations. Cue
reactivity tests consisted of a visual oddball task with images from the International
Affective Picture System and drug-related pictures. Evoked and induced gamma
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responses to target and non-target drug cues were analyzed using wavelet analysis and
coherence protocols via custom algorithms implemented in MatLab.
Results: Outpatient subjects with cocaine addiction completed the bio-behavioral
intervention and successfully increased SMR while keeping theta practically unchanged
in 12 sessions of neurofeedback training. Neurofeedback treatment resulted in a lower
EEG gamma reactivity to drug-related images in a post-neurofeedback cue reactivity test.
In particular, evoked gamma showed decreases in power to non-target and target drugrelated cues at all topographies (left, right, frontal, parietal, medial, inferior); while
induced gamma power decreased globally to both target and non-target drug cues. Also,
long range coherence was found to increase in specified electrode pairings post
neurofeedback. Our findings supported our hypothesis that gamma band cue reactivity
measures are sufficiently sensitive to functional outcomes of neurofeedback treatment.
Both evoked and induced gamma measures were found capable of detecting changes in
EEG responses to both target and non-target drug cues.
Conclusion: Our study emphasizes the utility of cognitive neuroscience methods based
on EEG gamma band measures for the assessment of the functional outcomes of
neurofeedback-based bio-behavioral interventions for addictive disorders. This approach
may have significant potential for identifying both physiological and clinical markers of
treatment progress. These methodologies can also be adapted and used in additional
pathologies to provide fast and reproducible evidence of treatment outcomes.
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I. INTRODUCTION
Drug addiction is a psychoactive substance use disorder (SUD), which can be
characterized by the physiological dependence of an afflicted individual upon a drug of
choice. This dependence is coupled with the withdrawal syndrome upon discontinuation
of drug use as well as physiological and psychological dependence and craving which
motivates an addict to partake in drug-seeking behavior. Drug addiction is a chronic,
relapsing mental disorder that results from the prolonged effects of drugs on the brain
(Dackis & O’Brien, 2001; Leshner, 1997; Wexler et al., 2001). Addiction leads to
behavioral, cognitive and socially adverse outcomes that incur substantial costs to
society. In 2006, it was estimated by the Substance Abuse and Mental Health Service
Administration (SAMHSA, 2007) that 19.9 million Americans used illicit drugs,
computing to roughly 8.0 % of the United States population. In 2007, there were 2.1
million active cocaine users, comprising 0.8 percent of the population. The National
Institute on Drug Abuse (NIDA) estimates that the total expenditure of drug-related
complications is greater than 500 billion dollars when healthcare, legal procedures and
job loss are considered.
Prolonged drug use can have profound effects upon the normal brain activity,
which can be recorded and measured through the use of qualitative EEG (qEEG)
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techniques. One of the most difficult drug addictions to treat is that of cocaine, as it is
associated with a high rate of morbidity and mortality. Patients suffering from cocaine
addiction typically show low interest in interventional treatment and hence treatment
programs are often plagued by low retention rates. Some qEEG studies have highlighted
components of EEG activity that are significantly altered by cocaine abuse. Several
studies have indicated that cocaine abusers show increased beta as well as delta and alpha
frequencies (Alper et al., 1990, 1998; Costa & Bauer, 1997; Herning et al., 1985, 1994ab;
Noldy et al., 1994; Prichep et al., 1996, 1999, 2002). These changes are thought to be
caused by the neurotoxic side effects of cocaine use and as a result of the withdraw
process (Alper, 1999).
In light of these findings an effective and non-invasive method for treating the
qEEG manifestations of addiction, and tracking the EEG changes over the course of
treatment is needed. Neurofeedback (NFB) is a technique employed to noninvasively
modify the electrical activity of the brain, including EEG, event-related potentials (ERP),
slow cortical potentials, and other electrical activity of cortical origin. Detailed review of
clinical efficacy of neurofeedback methods in SUD treatment and historic aspects of
biofeedback-based behavioral intervention for drug addiction can be found in Sokhadze
et al. (2008a) and Trudeau (2005).
Preoccupation with drug and drug-related items is a typical characteristic of
cocaine-addicted individuals. It has been shown in multiple accounts that prolonged drug
use has a profound effect on the EEG recordings of drug addicts when compared to
controls during cue reactivity tests. Cue reactivity refers to a phenomenon in which
2

individuals with a history of drug abuse exhibit excessive verbal, physiological and
behavioral responses to cues associated with their drug of choice (Carter & Tiffany,
1999; Franken et al., 1999), suggesting a rearranging of neuronal networks in the brain of
addicted individuals.
In cocaine addiction, items related to cocaine and drug paraphernalia are
repeatedly selected by the brain for conscious processing, and drug-related
representations are disproportionately tagged as relevant. While studies with active
cocaine users have indicated a strong physical reaction to drug-related stimuli (Carter &
Tiffany, 1999, Childress et al., 1994, 1999; Grant et al., 1996, London et al., 2000),
research examining cognitive aspects, for example attentional processes in cocaine
addiction has been limited (Franken et al., 2000; Robbins et al., 1997). Several research
studies provided support for the hypothesis that an attention alteration process takes place
in addicts (Hester et al., 2006; Lyvers, 2000; Robinson & Berridge, 1993), referred to as
the “attentional bias” (Franken et al., 1999, 2000, 2003), resulting in drug-related cues
attaining greater salience and motivational significance in substance abusing patients
(Garavan et al., 2000; Koob, 1999; Koob & Le Moal, 2001; Robbins et al., 2000).
Cue reactivity expressed in physiological and behavioral responses to stimuli
associated with the preferred substance of abuse (alcohol, nicotine, cocaine, heroin, etc.)
is relatively well explored (Carter & Tiffany, 1999; Childress et al., 1999; Drummond et
al., 1995; Ehrman et al., 1998; Lubman et al., 2000). One of the cognitive components of
cue reactivity in substance abusers is the preferential allocation of attentional resources to
items related to drugs (Lubman et al., 2000; Stormak et al., 2000). It has been proposed
3

that conditional sensitization in neural pathways associating incentives with stimulus
items may be responsible for cue reactivity (Franken, 2003; Weiss et al., 2001). Several
neuroimaging studies have reported effects associated with drug cue-related responses
and craving in cocaine addiction (Garavan et al., 2000; Hester & Garavan, 2004; Hester
et al., 2006; Johnson et al., 1998; Kilts et al., 2004). Restructuring and reallocation of
attentional resources suggests an over-attention to drug related cues believed to be
directly tied to the psychological symptoms of craving, which leads to repeated drug use
and relapse.
Several studies have been conducted to quantify the changes in qEEG values that
result from acute cocaine use as well as changes seen after prolonged abstinence, which
validated the findings that cocaine abusers typically elicit increased power in the beta,
delta and alpha frequency patterns as compared to controls (Alper, 1999; Alper et al.,
1990, 1998; Costa & Bauer, 1997; Herning et al., 1985, 1994b; Kilts et al., 2004; Noldy
et al., 1994; Prichep et al., 2002). A more informative method of testing qEEG
differences, as compared to resting, eyes closed EEG recordings, is the use of both visual
and auditory oddball tasks. SUD patients have been shown to illustrate a much higher
response to emotionally salient stimuli. Hence, in a visual oddball task involving neutral
(e.g., household items and nature pictures) and drug related images, drug addicts have
shown a much higher response to drug-related cues as compared to controls (Sokhadze et
al. 2008b).
Attentional bias toward the processing of salient stimuli is hypothesized to be a
cognitive process that is poorly controlled. Such automatic processing is similar to the
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orienting reflex to novel and significant signals. Drug abuse-related after-effects in the
medial prefrontal cortex (PFC) could be accompanied by impairments in emotional
regulation, and specifically in the inhibition of all motivations and emotions other than
craving (London et al., 2000; Volkow et al., 2003). Diminished PFC control of frontostriatal circuits allows more habitual responses mediated by the posterior and subcortical
(e.g., basal ganglia, striatum) structures to take over behavior regulation.
The gamma band (30-80 Hz), a high frequency rhythm of EEG activity, and more
specifically gamma activity within 30-40 Hz range, is thought to represent the allocation
of attentional resources and cognitive processes which take place in the brain. The
gamma frequency oscillation has been speculated to play a role in several important
cognitive functions. Widespread gamma band activity, which can be seen in the EEG
recordings, may be connected to feature “binding” from separate parts of the brain in the
attempt to make a coherent image from several perceived senses (Tallon-Baudry, 2003;
Tallon-Baudry & Bertrand, 1999; Tallon-Baudry et al., 1998, 2005). Additional data
involving new techniques such as magnitoencephalogram (MEG) and intra-cortical data
collection have implemented the gamma band, especially frequencies around 40 Hz, in
several higher level cognitive functions such as memory and learning through the
synchronization of cortical cell networks (Gray & Singer, 1989; Muller et al., 2000) .
These connections are thought to be reflected through calculating the power of the
filtered gamma band at a given electrode of interest when presented with the appropriate
stimulus.
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The oscillatory gamma response may be broken down into two main groups:
evoked and induced responses (Figure 1). These two gamma responses may be
discriminated on the basis of temporal localization and if they are time-locked to a
stimulus. The early, or evoked, gamma responses occur in the 0-200 ms post-stimulus
range. These early responses have been attributed to the early information processing
which have been linked to the sensation and perception of stimuli. These responses are
also time locked to a specific stimulus. In contrast, the late or induced gamma response
manifests in the 250-450 ms post-stimulus time window, depending on stimulus modality
and complexity. These induced responses are not time locked to a stimulus and are seen
in task conditions which require pattern recognition or a higher-order processes of the
short-term memory. As such, these patterns have been linked to the possible indication
of perceptual and cognitive processes. Based on these variable responses it is
hypothesized that the gamma band is multifunctional and represents a broad based
integration of attentional resources and cognitive patterns.
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Figure 1: Illustration of time locked early evoked
gamma and late induced gamma responses

It should be noted that the early time locked gamma response is less affected by
changes in stimulus type, task descriptions and level of task complexity. As a result of
these findings it has been suggested that early, time locked gamma is actually a sensory
oriented process.
An additional measurement indicator used to highlight differences in attentional
resources altered during drug addiction is dense-array event-related potentials (ERP).
The most commonly studied ERP is the so called P300 which looks at the window 300600 ms post stimulus. It has been suggested that the amplitude of this waveform may be
attributed to the brain allocating attentional resources while the latency period has been
7

correlated to the stimulus classification processes. The P300 may be subdivided into
amplitudes occurring over either the frontal regions or centro-parietal regions, and are
named P3a and P3b respectively. When collected during the administration of an oddball
task, as was done during this research, the P3a is correlated with an orientation of
attention to a stimulus, while P3b is thought to represent sustained attention upon the
stimulus (Katayama & Polich, 1998).
It has already been reported by the authors that significant changes result in the
ERP as a result of chronic cocaine use and are observable even after long periods of
abstinence in recovering cocaine addicts (Sokhadze et al., 2008b). Changes reported
included extended P300 latency. It was also shown that larger P3a and P3b amplitudes
would be seen in addicts in response to drug cues as compared to controls. The results
clearly demonstrated heightened ERP responses to drug-related cues in addicted
individuals. It is reasonable to propose that excessive reactivity during exposure to drug
cues in addicts can be detected not only in ERP but also in evoked and induced gamma
responses. It is possible that evoked gamma responses may be even more sensitive than
the P300 component of ERP which is known to be a pre-morbid trait in SUD and many
other psychopathologies such as schizophrenia, bipolar disorder, affective disorders
(Polich & Herbst, 2000).
It is thought that neurofeedback may be a non-invasive method of treatment,
which can lower drug-oriented attention and behavior, including craving. These changes
may be measurable through the use of qEEG techniques such as gamma power analysis
and gamma coherence calculation. Wave coherence is defined as a measure of
8

destructive interference between two waves. EEG coherence analysis is a technique that
investigates the pair-wise correlations of power spectra obtained from different
electrodes. It measures the functional interaction between cortical areas in different
frequency bands. A high level of coherence between two EEG signals indicates coactivation of neuronal populations and provides information on functional coupling
between these areas (Franken et al., 2004). EEG coherence abnormalities have been
reported in patients with cocaine (Roemer et al., 1995), heroin (Fingelkurts et al.,
2006ab), and marijuana dependence (Struve et al., 1989, 1999, 2003). In our research the
EEG data was segmented into the appropriate frequency bands and the coherence
calculated over time for a given frequency range. Coherence between electrode pairs was
evaluated using the Brain Electrode Source Analysis software package. Bitmap images
produced using this software package were then passed to MatLab for quantitative
analysis using a custom algorithm.
Gamma power, representing the relative amount of gamma activity at a given
electrode in time, was estimated using a waveleting technique implemented in MatLab.
Wavelet transforms are a multi-resolution analysis technique, which allows for the EEG
signal to be split into a user-defined number of sub-bands. When implemented in code it
may be visualized as a series of high and low pass filters which result in the signal being
split into smaller and smaller portions. These resulting sub-signals can then be passed to
a band pass filter written to allow the passage of gamma band frequencies. After passing
all sub-band signals through the band pass filter it is then possible to summate these
waveforms to attain an accurate estimate of the gamma frequency of a given electrode in
time.
9

It is our hope that through measuring pre and post-treatment normalized power
indices of gamma band activity and long range coherence, we will be able to show
mediated responses to drug related items in post-neurofeedback cue reactivity tests in
cocaine addicts. Both evoked and induced gamma power were analyzed at pre and postneurofeedback training time points and then compared for any statistical differences
between topographic groupings of electrodes in the hope of highlighting topographic
differences in the left and right hemispheres as well as in the anterior and posterior
regions of the brain.
Our neurofeedback training protocol included up to 3 motivational interviewing
(MI, Miller & Rollnick, 2002) sessions as an integral part of biobehavioral intervention
in outpatients, since we always emphasized that outpatient treatment programs were more
effective in drug abusers when neurofeedback training is combined with additional
cognitive-behavioral therapy treatment modalities (Sokhadze et al., 2008a). Several
studies of brief MI with cocaine abusers (Stotts et al., 2001, 2006), including our own
pilot study (Sokhadze et al., 2005), report that cocaine dependent patients presenting with
lower initial motivation to change habits were more likely to achieve abstinence
following brief MI intervention than those who did not receive MI intervention. Our
hypothesis in this study was that following 12 sessions of neurotherapy (SMR/theta
neurofeedback and MI) outpatient cocaine users will show decreased evoked and induced
gamma frequency response to both target and non-target drug-related stimuli and higher
long range coherence during post neurofeedback cue reactivity tests.
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II. SUBJECT RECRUITMENT AND DEMOGRAPHICS

A. Subjects: recruitment process
Patients with current cocaine use or a cocaine dependence record were referred
from the University of Louisville Hospital drug abuse treatment outpatient services, such
as Jefferson County Alcohol and Drug Abuse Center (JADAC), and other psychiatric
ambulatory units. Dr. Stewart, a Medical Director at JADAC and a clinical consultant at
two residential addiction treatment centers located in the Louisville Metro Area, provided
referrals through these programs and conducted Motivational Interviewing sessions.
Participating subjects with SUD were provided with full information about the study
including the purpose, requirements, responsibilities, reimbursement, risks, benefits,
alternatives, and role of the local Institutional Review Board (IRB). The consent forms
were reviewed and explained to all subjects who expressed interest in participating. If the
individual agreed to participate, she/he signed and dated the consent form and received a
copy countersigned by the investigator who obtained consent.
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All procedures were conducted within the facilities of the Department of
Psychiatry and Behavioral Science and the University of Louisville Hospital Outpatient
Clinic. Initial contact with prospective participant was typically made via telephone
screening to ensure participants met inclusion criterion. Subjects participating in the
research study were reimbursed for their time and transportation costs. Payment methods
followed the University of Louisville Health Science Center’s Committee for the
Protection of Human Subjects’ guidelines concerning reimbursement for research time
and parking. Participants were paid $20/hour for completing required research activities
(e.g., EEG/ERP tests, providing urine sample, completing self-report forms,
neurofeedback session, etc.) at each visit.

B. Psychiatric status questionnaires, drug use and psychosocial functioning screening
The Structured Clinical Interview for DSM-IV (SCID I) (First et al., 2001) was
used for Axis I diagnoses. Posttraumatic Stress Disorder (PTSD) was assessed using The
Post-traumatic Symptom Scale - Self Report (PSS-SR) (Foa et al., 1989, 1997)
questionnaire. The Beck Depression Inventory (BDI-II, Beck et al., 1996) was used to
measure symptoms of depression. PTSD and depression scores were assessed both
before and after treatment. Handedness of patients was assessed using the Edinburgh
inventory (Oldfield, 1971). Scores from the Addiction Severity Index (ASI) were used to
measure problem severity in the areas of medical, employment, drug abuse, legal, family,
social, and psychiatric difficulties (McLellan et al., 1980). Cocaine Negative
Consequences Checklist (Michalec et al., 1996) was used to assess short-term and long12

term adverse effects resulting from cocaine use. Psychosocial adjustment was assessed
using the Social Adjustment Scale (SAS) (Weissman & Bothwell, 1976).
Qualitative urine toxicology screens (DrugCheck 4, NxStep, Amedica Biotech
Inc., CA) were conducted in each subject to confirm cocaine abuse. In addition,
qualitative urine toxicology screens for amphetamines, opiates and marijuana were
performed to assess presence of additional abused substances. A positive test for
marijuana was not considered an exclusion criterion. Qualitative Saliva drug test (ALCO
SCREEN, Chematics, Inc., IN) was used during each visit to rule out current alcohol use.
Urine drug screens were conducted at the intake stage, and at the post-neurofeedback
assessment stage.

C. Subjects Demographics
Ten cocaine abusing/dependent subjects (two females, eight males) mean age,
44.6 ±8.3, range 35-54 years, 70% Afro-Americans) participated in the study. Eight of
them were current cocaine users and all subjects displayed no additional comorbid mental
conditions. Seven subjects tested positive for cocaine, and seven of them also tested
positive for marijuana use. One tested positive for opiates and admitted the use of heroin
along with crack cocaine. Two subjects who did not test positive were recovering addicts
enrolled in this study after the inpatient JADAC rehabilitation course with an abstinence
period less than 30 days. Hospital records confirmed their use of cocaine within one
month of the baseline cue reactivity test. One of them tested non-conclusive positive for
cocaine at intake, but a repeated test on the following week did not confirm drug use.
13

Therefore the majority of our outpatient population consisted of current cocaine users,
with more than half of them using marijuana as a second drug of choice.
The preferred method of drug administration was smoking crack cocaine. Only
one of the cocaine addicts in this study used cocaine intravenously. The majority of
addicted subjects (80%) reported regular use of nicotine/smoking. None of the subjects
were simultaneously in any treatment program other than Narcotics Anonymous (NA),
Alcoholic Anonymous (AA), or local church-based anti-drug counseling programs. All of
the subjects except one were right-handed. Subjects enrolled in the study were fully
informed about the nature of this research and signed informed consent forms approved
by the Institutional Review Board (IRB) of the University of Louisville. For biological
specimen collection (urine drug screens and alcohol saliva tests), subjects signed a
separate consent form also approved by the IRB within the same study protocol.
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III. DATA COLLECTION

All stimulus presentation, behavioral and subjective response collection was
controlled via computer running E-prime software (Psychology Software Tools [PST],
PA). E-Prime is a graphical programming language that allows for the creation of
psychology experiments according to a user-defined hierarchy of stimulus presentation
and signal recording. Visual stimuli were presented on a 15" flat-panel display.
Behavioral responses (e.g., reaction time) were collected with a 5-button keypad (Serial
Box, PST, PA). Subjects were instructed to press key number 1 when they were
presented with a target category picture, and to not press any key when presented with a
non-target category images. In all experiments subjects were seated in a chair with their
chin in a chinrest. The chinrest was placed so that subject's eyes were 50 cm from the
center of the flat panel screen. Breaks were provided every 10 minutes. All EEG data
were acquired with a 128-channel Electrical Geodesics system (Net Station 200, v. 4.0)
(Electrical Geodesics Inc. [EGI], OR) running on a Macintosh G4 computer.
EEG data were sampled at 500 Hz, 0.1 - 100 Hz analog filtered, and referenced to
the vertex (C3). The Geodesic Sensor Net was a lightweight elastic thread structure
containing silver/silver-chloride electrodes housed in a synthetic sponge on a pedestal.
The sponges were soaked in a potassium chloride solution to render them conductive.
15

Sensor impedance was maintained below the range recommended by the EGI manual (40
kOhm). Stimulus-locked EEG data were segmented off-line into 1000 ms epochs
spanning 200 ms pre-stimulus to 800 ms post-stimulus around the critical stimulus events
(Figure 2).

Figure 2: Illustration of a single trial epoch with a stimulus presentation
at 200 msec. Early and Evoked Gamma waveforms are shown.

For example in our cue reactivity task the events were: (1) neutral target of
household category, (2) neutral non-target of household category, (3) neutral target of
animal category, (4) neutral non-target of animal category, (5) drug target, (6) drug nontarget, and (7) neutral non-target nature images (standards). Frequency of targets for each
category (household, animals, and drug) was 25%. There were always 50% of neutral
pictorial (all non-drug, neutral other than household or animal category) standards in each
block of trials. Data were digitally screened for artifacts (eye blinks, movement, etc.) and
bad trials were removed using built-in EGI Net Station artifact rejection tools. The
remaining data were sorted (segmented) by condition and exported for further analysis
using MatLab and BESA routines described below in the data analysis section. EEG sites
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presented in Figure 3 were selected for evoked and induced gamma response analysis and
Figure 4 shows the major regions of the brain to allow for location comparison.

Figure 3: Illustration of the 128 electrodes used to collect EEG data with the
eight electrodes selected for analysis highlighted in green. The list to the right
yields the electrodes respective numbers and the corresponding name in the 10-5
naming system. Electrodes labeled with an F are located in the frontal lobe while
those labeled with a P are located in the parietal lobe.
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Figure 4: Pictorial representation of the brain split into the five major regions. All regions
can be found on both the left and right hemispheres. All of our electrodes are found within
the parietal and frontal lobes. In Figure 3, all electrodes beginning with the letter F represent
a frontal electrode, and likewise all those beginning with the letter P represent a parietal
electrode.

The pictorial material was taken from the International Affective Picture System
(IAPS, Lang et al., 2001). Numbers of each IAPS picture used in the study are available
upon request. Cocaine images were selected and validated by a co-author (ES) during his
post-doctoral fellowship at Rice University (Houston, TX). In that prior study (Potts,
Martin, Stotts, George, & Sokhadze, unpublished report), 25 cocaine-abusing patients
rated 115 cocaine-related images on a 5-point scale (1 being low and 5 being high) as to
how evocative each drug image was. The mean rating for the entire set was 2.66,
SD=0.48. Thirty images of high rating (all 30 with a mean rating above 3.0) were
selected for use in this study. Valence, arousal, and dominance rates were matched
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within each set of images in neutral categories using ratings from the IAPS database
(Lang et al., 2001). The experiment used pictures from two neutral categories as targets:
neutral (household items, animals), and one drug category (cocaine and drug
paraphernalia). Three examples of each image category are shown in Figure 5 below,
additional images used in this experiment may be found in the appendix section.
A. Neutral Household photos:

B Neutral Nature photos:

C. Cocaine and Drug Paraphernalia Photos:

Figure 5: Examples of images used in the cue reactivity test for the following three blocks; A.)
Neutral Household, B.) Neutral Nature and C.) Cocaine and Drug Paraphernalia.
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Subjects were instructed to respond to stimulus items from one of the categories,
ignoring the others within each block (e.g., targets were household items in a “neutral”
block, Figure 6). The order of blocks (with 240 trials per block) was counter-balanced. In
the task a stimulus was presented on the screen for 200 ms, whereas recording of EEG
data occurred for 1000 ms (200 ms pre-stimulus and 800 ms post-stimulus). Inter-trial
interval varied in 1100~1300 ms range to avoid anticipation effects. Each of the three
blocks of trials was followed by a short break. The experiment took approximately 30
minutes to complete. The cue reactivity test was followed by a 10-15 min cool-down to
allow cocaine cue-induced craving to fade out. Repeated cue reactivity was administered
within a week after completion of 12 sessions of neurofeedback training.

Figure 6: Illustration of cue reactivity experiment protocol. Each
stimulus is presented for 200 ms and a variable weight period of
1100-1300 ms is observed between stimuli.
20

A. Neurofeedback procedure:
During neurofeedback treatment the subjects were trained to enhance amplitude
of SMR within a specified frequency band (12-15 Hz at C3 monopolarly referenced to
the left mastoid) and/or decrease (suppress) amplitude of Theta frequency bands (4-7 Hz
at F3 monopolarly referenced to the left mastoid) over 12 sessions (2 sessions/per week
rate). Visual and auditory real time online feedback was provided using a C-2 J&J
Engineering device with Physiodata software (J&J Engineering Inc, Poulsbo, WA). Each
session in the SMR/Theta protocol was conducted using a standardized procedure lasting
no more than 30 min.
Immediately after attachment of electrodes, impedance check (< 5 kOhms) and
four min long baseline recording, subjects performed four, seven-min long blocks of
neurofeedback training (operant conditioning of specified EEG frequencies – suppression
of Theta and enhancement of SMR). EEG was recorded at a sampling rate of 1024 Hz
recorded from C3 with reference on the left mastoid and the ground electrode placed on
the right earlobe. The EEG biofeedback procedure was based on Lubar’s ADHD
protocol in its late modifications (Lubar, 2003), and the first part of Scott & Kaiser’s
modification of Peniston’s brainwave training protocol for alcohol/drug abuse treatment
(Scott et al., 2005). During neurofeedback training, patients were trained to increase their
SMR amplitude and decrease their slow wave activity (e.g., theta). Our neurofeedback
training protocol therefore consists of rewarding enhanced EEG amplitudes at the
sensorimotor strip (C3) in the 12-15 Hz frequency range, while simultaneously inhibiting
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excessive low frequency (4-7 Hz) at the frontal F3 site. Self-adjusting thresholds were
used for continuous visual and auditory feedback.

B. Motivational Interviewing procedure
Motivational Interviewing (MI) (Miller & Rollnick, 2002; Treasure, 2004) is a
brief psychotherapeutic intervention for behavioral change aimed to bring about rapid
commitment to changing addictive behaviors. The MI (also referred to as Motivation
Enhancement Therapy [MET]) was designed to increase the compliance and probability
of treatment entry and abstinence (Burke et al., 2003). This behavioral therapy is
considered to be especially useful for the drug-dependent individuals who are ambivalent
about changing their habits, since MI was specifically targeted to less motivated
individuals. Dr. Stewart, a specialist in addiction psychiatry, who is trained in MI,
conducted forty- five minute MI sessions. Each subject received at least 2 sessions of MI,
while 5 subjects from the group volunteered for a third (optional) MI session. There was
at least a one-week waiting period between MI visits.

22

IV. DATA ANALYSIS

A. Wavelet Power Analysis
Data were collected and stored using Net Station (EGI). Immediately following
the cue reactivity test the EEG data were tagged according with the appropriate triggers
in Net Station and segmented into the appropriate response categories (e.g. drug-target,
drug-non target, neutral-target and neutral-non target) and exported to MatLab for
wavelet analysis. Waveleting was used to elucidate the frequency components of a signal
as they vary in time. By plotting the result of the filtered wavelet data it was possible to
measure the precise timing and strength of the gamma response, both early evoked and
late induced, in relation to a given stimulus. The data were subjected to wavelet analysis
using the continuous wavelet transform (Eq. 1), which can be found in the wavelet
toolbox of MatLab.

(1)
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The mother wavelet (ψ) used in this application was the Morlet window, and 128
coefficients were found for each signal. Using this window implies subtracting a userdefined constant from the wave followed by localization using a Gaussian window. A
pictorial representation of the Morlet Window is shown below in Figure 7. The
mathematical representation of the Morlet window is also outlined in equations 2, 3 and
4.

Figure 7: Plot of the Morlet window used in our
continuous wavelet transform.

(2)
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(3)
Equation 3: Constant subtracted from the base wave
for the construction of the Morlet Window

(4)
Equation 4: Normalization factor used in the
construction of the Morlet Window.

The waveleted signal was passed on for band pass filtering using a custom design
Harris 7 window (Figure 8). The Harris window used 725 samples and was designed to
allow the complete passage of signals from the 30-40 Hz range. An attenuation band of
one Hz was present in the system. The resulting signals now only consisted of the
gamma band frequency components and could be summated to yield the relative power
of the gamma band. A flow-chart representation of data processing is shown on Figure 9.
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Figure 8: From top to bottom, 1) the custom Harris seven window
with 725 samples, 2) the impulse response and of the designed band
pass filter 3) the band pass filter displaying a pass band of 30-40 Hz
with a 1 Hz transition band on either side of the pass window.
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Figure 9: Flow chart representation of the
calculation of Gamma Power.

1. Statistical analysis of Gamma Power
Statistical analysis was performed on the subject-averaged data using the subject
averages as observations. Each single gamma oscillation trial was analyzed for preselected frontal and parietal EEG sites and time window (0-200, 250-450 ms poststimulus). Data for each dependent gamma EEG variable was analyzed using a repeatedmeasures ANOVA. Factors included Stimulus (target or non target), Cue (drug or
neutral), Hemisphere (right or left) and Topographic location (anterior or posterior).
Using SPSS (v. 18) analysis packages, a model was created to test for significant
interactions between electrodes in both lateral (inferior) and medial locations pre and post
neurofeedback training in both the early and late gamma windows. In all ANOVAs,
Greenhouse-Geisser corrected p-values were employed where appropriate.

B. Coherence Calculations
Coherence was calculated using a combination of the Brain Electrical Source
Analysis (BESA 5.1 Grafelfing, Germany) software packages and custom software
programs developed in MatLab. Data was exported in raw format from Net station to
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BESA. Toolboxes within BESA allow for the uploading of surface electrode
coordination files and stimulus classification. Once the data was loaded and coordinated
to the appropriate electrode source, it could be segmented into separate sets according to
the cue reactivity test trial (e.g. drug-target, neutral target…). BESA also contains
artifact detection protocols, which allow for the elimination of contaminated trials and
channels based upon phase, amplitude and low signal thresholds. Raw data was scanned
and eliminated of all possible artifacts before coherence values were calculated.
Coherence is measured in BESA according to three values. The first is the timefrequency signal, which is simply the amplitude of the signal at a given point in time for
the frequency range specified by the user. The second is the actual coherence of the two
wave amplitude, which is measured by finding the correlation of the time-frequency
signals and normalizing this value over all the trials of that particular cue (ie. target
drug…). The final value is the phase locking value, which measures the phase
similarities between the two recorded electrode waveforms.

Figure 10 shows a

summary of the values found in BESA, along with how these values are combined into a
final coherence value between zero and one.
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Figure 10: Recreated from BESA instruction manual, this image shows the three
relevant values found when calculating the coherence using BESA, namely the timefrequency signal, the coherence and finally the phase locking value. These values are
found over all trials and used to yield an overall coherence value according to the
bottom table.

Within BESA it was possible to create a montage displaying electrodes of
interest. Hence a custom montage consisting of the eight electrodes previously outlined
in Figure 4 was created and applied to the raw data prior to artifact scanning and
calculation of coherence. Using the coherence toolbox, BESA returns a bitmap image
relating coherence in the form of a scaled color mapping system (blue = .0 correlation
coefficient to red = 1.0 correlation coefficient). Each image displays a set of mappings,
which show each electrode in the montage referenced to a single electrode. Each
possible combination of reference electrodes were created (e.g. for the eight electrode
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montage, eight images were created, each using one of the eight electrodes as a
reference.) An example of the images created in BESA is shown below (Figure 11).
These mapping images were then be saved and exported into MatLab for qualitative
quantification using a custom computer program.

Figure 11: Representative image of the bitmaps created in BESA. Eight such
images were created for each patient at each for each condition and stimulus (target
vs. non-target) at pre-and post neurofeedback time points.

Using a custom made MatLab program, these bitmap images were segmented into
eight smaller images, one for each electrode. The program then segmented each
electrode images into a series of windows over a 100 ms width and a 5 Hz height. For
each electrode image there were 848 possible windows that cover the 0-200 ms (early) or
the 250-450 ms (late) post stimulus time frame and 30-45 Hz frequency band. Once the
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windows were created each individual window was analyzed for coherence. To do this
each window was loaded and compared pixel by pixel to a color matrix. The color matrix
assigns a scaling value over the interval of [0:1] with a step size of 1/512 (512=the
number of possible red, green and blue color combinations which compose an individual
pixel in the matrix). Each pixel in the image possesses a RGB value which can be
compared to the color matrix using the following distance calculation:

(5)

Equation 5: Distance formula calculation. Used to calculate
the Euclidian distance between the RGB values of a given pixels
and each RGB combination in the scaling matrix.

Figure 12: Flow chart illustration of the segmentation process, a complete
bitmap image is loaded in MatLab, an individual electrode is then segmented
out, and an entire region is iteratively swept to create test windows.
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This calculation was made to every point in the scaled color matrix and the
minimum value was taken as the coherence value for that pixel. This process was
repeated for each pixel contained within the specified window. These values may then be
summated to yield the total coherence over the loaded window. Each of the 848 windows
for the electrode image was analyzed and the maximum of the 848 resulting values was
taken as the gamma band coherence at a given time frame. Images were created and
analyzed for each patient for both target and non-target drug cues, and at both early and
late time points. Results were then statistically analyzed using a student’s t-test to
determine which electrodes showed statistically higher responses post neurofeedback.
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V. RESULTS

A. SMR and Theta changes in neurofeedback sessions
All subjects successfully completed twelve 25-30 min long sessions of SMRup/theta-down sessions and at least 2 Motivational Interviewing sessions (conducted by
Dr. Stewart and his associate, addiction psychiatry fellow Dr. Husk). The mean increase
of the SMR amplitude as compared to daily baseline level across all neurofeedback
sessions was 17.06 percent, SD=15.04 (t=3.20, p=0.007), but mean change of theta
amplitude was not significant (0.99 ± 5.71 percent, t=0.49, p=0.311, n.s.). Regression
analysis showed that the increase of SMR as compared to baseline vs. neurofeedback
session numbers was not linear (y=0.808x+10.53, r2=0.24, F=3.21, p=0.103, n.s., Figure
13). Considering that out of 10 participants only 8 were available for the postneurofeedback (within a week after completion) clinical assessments and cue reactivity
test, all results are reported for 8 subjects (i.e., hereafter all statistical calculations used
N=8/group).
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Figure 13: Changes in SMR levels compared to baseline over the
course of 12 neurofeedback sessions.

B. Effects of NFB on RT and EEG gamma power in cue reactivity test (post-treatment)
Behavioral responses. There were no significant differences in reaction time (RT, Mean
603.6 ± Standard Deviation 120.6 ms pre- vs. 576.9 ± 122.4 ms for drug targets postneurfeedback, n.s.) and accuracy (percentage of commission and omission errors, 10.9 ±
11.7 percent pre vs. 11.6 ± 13.2 percent across all targets, n.s.) in the cue reactivity test
following neurofeedback treatment.
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C. Effects of NFB on evoked (early) gamma responses
Neurofeedback affected predominantly evoked early gamma responses to nontarget drug stimuli bilaterally at the frontal and parietal sites (all p<0.05). The power of
gamma oscillations to non-target drug cues significantly decreased post-treatment with
decreases ranging from -23.6 percent (P8) up to -44.94 percent (P3), mean - 35.84
percent with SD across the EEG channels 7.43 percent. Gamma responses to target drug
cues were less pronounced (-9.65 ± 7.21 percent) and were significant only at F2, F8, P3,
and P7 sites. Changes of gamma power in response to target and non-target drug cues at
each EEG recording site are presented in Table 1 below.
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TABLE I
CHANGES IN GAMMA POWER IN THE EARLY AND LATE TIME
FRAMES
EEG
Channel/condition

Early Evoked Gamma Power

Late Induced Gamma Power

Pre

Post

%
Change

F(1,14)

Sig.

Pre

Post

%
Change

AFz-Non-target
drug

F(1,14)

Sig.

0.399

0.347

-15.0

18.8

0.001 **

0.436

0.297

-46.8

182.4

0.000***

AFz-Target Drug

0.520

0.499

-4.2

0.4

0.524

0.563

0.472

-19.3

28.2

0.000***

F1-Non-target
drug

0.392

0.321

-22.1

8.5

0.014 *

0.429

0.355

-20.8

8.1

0.014*

F1-Target Drug

0.495

0.467

-6.0

1.0

0.332

0.552

0.436

-26.6

15.0

0.003**

F2-Non-target
drug

0.400

0.319

-25.4

18.1

0.001***

0.427

0.360

-18.6

7.3

0.018*

F2-Target Drug

0.523

0.478

-9.4

7.2

0.023*

0.563

0.445

-26.5

17.4

0.002**

F7-Non-target
drug

0.382

0.318

-20.1

11.4

0.006**

0.426

0.309

-37.9

59.1

0.000***

F7-Target Drug

0.46

0.485

5.2

0.9

0.376

0.546

0.475

-14.9

6.5

0.029*

F8- Non-target
drug

0.388

0.299

-29.8

77

0.000***

0.436

0.314

-38.9
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0.000***

F8-Target Drug

0.499

0.469

-6.4

2.6

0.139

0.476

0.467

-1.9

0.0

0.924

P3- Non-target
drug

0.387

0.276

-40.2

22.5

0.001**

0.419

0.285

-47.0

55.0

0.000***

P3-Target Drug

0.513

0.442

-16.1

4.1

0.071

0.432

0.438

1.4

0.0

0.958

P4- Non-target
drug

0.399

0.325

-22.8

5.5

0.039*

0.436

0.322

-35.4

20.5

0.001**

P4- Target Drug

0.465

0.453

-2.6

0.2

0.641

0.536

0.457

-17.3

12.3

0.006**

P7- Non-target
drug

0.386

0.281

-37.4

23.7

0.000***

0.417

0.279

-49.5

120.8

0.000***

P7-Target Drug

0.496

0.433

-14.5

3.7

0.082

0.554

0.433

-27.9

24.3

0.001**

P8- Non-target
drug

0.379

0.326

-16.3

5.0

0.048*

0.438

0.313

-39.9

38.7

0.000***

P8-Target Drug

0.456

0.465

1.9

0.1

0.71

0.560

0.465

-20.4

26.1

0.001**

Cue (drug, neutral) had main effects both at medial (F1, F2, P3, P4) and lateral
(i.e., inferior, F7, F8, P7, P8) EEG channels with more at medial (F=9.43, p=0.001) as
compared to lateral (F=5.05, p=0.044). The Stimulus (non-target, target) main effect was
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highly significant both medially and laterally (medial, F=268.05, p<0.0001; lateral
F=196.75, p<0.0001).
D. Effects of NFB on induced (late) gamma responses
Neurofeedback affected induced gamma responses to both target and non-target
drug stimuli bilaterally at most frontal and parietal sites, except responses to targets at P3.
The power of gamma oscillations to non-target drug cues significantly decreased posttreatment (across all channels, mean -47.17 ± 9.88 percent), while decreases to target
drug cues were also significant but slightly less expressed (-21.58 ± 5.09 percent).
Cue (drug, neutral) had main effects both at medial and lateral EEG channel
groups (F=34.28, p<0.001, and F=27.20, p<0.001 respectively). The Stimulus (nontarget, target) main effect was also significant medially and laterally (medial, F=80.52,
p<0.0001; lateral F=1173.16, p<0.0001).

E. Topographic differences and interaction effects
Early gamma responses showed a Stimulus (non-target, target) X Treatment (pre-,
post-NFB) interaction both at medial (F=34.82, p<0.001) and lateral (F=29.82, p<0.001)
channels with more of a pronounced decrease in gamma activity to non-target compared
to target cues. A three-way Stimulus X Cue (drug, neutral) X Treatment interaction was
significant only at the medial channel group (F=7.99, p=0.015) and can be described as a
more significant decrease to non-target rather than target drug cues following
neurofeedback training. There was a tendency for a Hemisphere (left, right) X
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Topography (anterior, posterior) X Treatment interaction, but the effect did not reach
significance (F=4.56, p=0.056, n.s.).
Induced gamma responses showed a Stimulus (non-target, target) X Treatment
(pre-, post-NFB) interaction only at lateral EEG channels (F=60.78, p<0.001). Again, the
effect manifested as a clearer global decrease in gamma power to non-target cues (Figure
15). A Stimulus X Cue X Treatment interaction was significant both at the medial
(F=6.29, p=0.022) and lateral (inferior) channels (F=4.72, p=0.049) and was
characterized by more significant decreases in gamma induced by non-target compared to
target drug cues post-neurofeedback. Figures 14 shows a relatively more visible decrease
of evoked and induced gamma responses to non-target as compared to target drug cues
after neurofeedback based therapy.
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Figure 14: From top to bottom: 1.) Gamma Responses of the grand average of the 4
medial electrodes to target drug stimuli, 2.) grand average of the 4 lateral electrodes to
target stimuli, 3.) grand average of the 4 medial electrodes to non-target drug stimuli, and
4) grand average of the 4 lateral electrodes to non-target stimuli.
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Figure 15: Analysis of gamma response change (in percent) across electrodes.
Results show a higher percent change to non-target rather than target stimuli (left),
and all electrodes changing in a consistent pattern (i.e. Topography was not a
significant factor in percent change of gamma power).
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F. Coherence Results
Coherence was shown to increase in for both conditions (ie. target and non-target
drugs) in both early and late gamma time frames. Despite the fact that many of the
electrodes did show improvement, relatively few were statistically significant. When
considering early gamma targets showed statistically significant increased coherence at
the F7/F1, F1/P4 and F1/P8 electrode pairs and non-target cues likewise showed
statistical improvement at the F7/F1 electrode pair only. In contrast the target cues
showed several more statistically significant increases: F7/F1, F7/P4, F7/P8, F1/P4, and
F1/P8 all showed a p-value less than .05. Finally, non-target cues showed statistical
improvement in only the F7/F1 position. Figures 16-19 show graphical depictions of
coherence improvement for each cue in both time frames, as well as which electrode
pairs show statistical improvements.
While statistically relevant improvement was seen, it was highly limited and
failed to show a widespread improvement in long range coherence. It is the belief of the
authors however, that this data may be slightly skewed based upon comparing single
electrodes only. It is possible within BESA to create montages of entire brain regions,
effectively taking groups of electrodes for a brain region and combining them into a
single grand average waveform. With this technique it would be possible to highlight
areas of baseline coherence abnormalities between controls and drug addicted patients
and also to show increases in regional brain coherence rather than simply a pair-wise
electrode comparison which may yield an improved analysis of long range coherence.

41

Figure 16: Top: Long range early gamma coherence to target drug cues pre and post
NFB. Bottom: Electrode pairs showing statistically relevant improvement according to
one sample t-test on difference between the pre and post NFB values.
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Figure 17: Top: Long range early gamma coherence to non-target drug cues pre and
post NFB. Bottom: Electrode pairs showing statistically relevant improvement
according to one sample t-test on difference between the pre and post NFB values.
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Figure 18: Top: Long range late gamma coherence to target drug cues pre and post
NFB. Bottom: Electrode pairs showing statistically relevant improvement according to
one sample t-test on difference between the pre and post NFB values.
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Figure 19: Top: Long range late gamma coherence to non-target drug cues pre and
post NFB. Bottom: Electrode pairs showing statistically relevant improvement
according to one sample t-test on difference between the pre and post NFB values.
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G. Clinical evaluations and drug tests after NFB and MI
Results of the clinical evaluations showed decreased perceived depression and
stress. Following neurofeedback sessions subjects reported to have reduced depression
scores (from 22.2 ± 6.9 at pre- to 13.6 ± 8.7 at post-NFB, two-tailed Student’s t-test,
t=3.30, p=0.004) as measured by the BDI-II (Beck et al., 1996); additionally there was a
reduced stress score (from 29.9 ± 8.6 to 20.1 ± 13.9, t=1.95, p=0.041) as measured by the
PSS-SR (Foa et al., 1989, 1997). Post-neurofeedback urine drug screens showed a
marginal decrease in positive cocaine tests (t=1.96, p=0.04) and a significant decrease in
positive tests for marijuana use (t=2.44, p=0.018). Most of the patients reported a
decrease in the amount of cocaine and marijuana used and improvements in social status
(i.e., resuming study at school, employment, housing, financial security, problems with
law, etc.); however, in this study we did not have any independent sources (e.g., family
members, neighbors or social workers reports) to confirm self-reported data collected
from our subjects. Considering that from ten participants originally enrolled in this
neurofeedback study all planned clinical, behavioral, and EEG data were collected from
eight, an acceptable retention rate was maintained.
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VI. CONCLUSIONS

Our study attempts to develop and quantify methods of analytically quantifying
the effects of neurofeedback procedures, specifically in cocaine addiction. Substance
abuse disorder is a psychoactive disorder, which causes changes in the brain that result in
a misallocation of attentional resources to drug related items. These changes are a
consequence of both the neurotoxic effects of the drugs being used by the patient and as a
result of the withdraw process experienced upon cessation of drug use. Drug addiction as
a whole is projected to cost approximately 500 billion dollars when the cost of healthcare,
job-loss and legal ramifications are considered.
Previous studies have highlighted specific differences found in the EEG patterns
of patients suffering from cocaine addiction. These differences include abnormal levels
of theta and delta band frequencies. However, very little work has been done previously
to quantify differences in the gamma band, which comprises of frequencies ranging from
30-80 Hz in the EEG waveform. The gamma band may be split into two major
components, namely evoked and induced. The evoked gamma response are also referred
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to as early gamma responses, as they occur in the 0-200 ms post stimulus range and are
time locked to a given stimulus. These responses show very little variance to different
types or different complexities of stimuli. Hence they are thought to represent a prerecognition process within the brain.
In contrast to these findings the induced, or late gamma, occurs in the 250-450 ms
post stimulus range, and is not time locked to a stimulus. The induced gamma response
also shows a much higher variation in amplitude and latency depending on stimulus type
and complexity, suggesting a role in conscious cognitive thought processes. Since it is
known that substance abusing patients show an increased response to drug related items
in a cue reactivity test, it makes sense to investigate changes in the gamma band as a noninvasive method to quantify the effects of neurofeedback over the course of treatment.
In this experiment we set out to quantify two indices of the gamma band that may
be used to track the progress of treatment. Specifically these two methods were the
calculation of gamma power and of long-range gamma coherence between electrodes.
Gamma power was found by submitting the raw EEG signal from a given channel to a
waveleting routine implemented in MatLab. This process allowed for the separation of
specific frequency bands as they occur in time. Our custom waveleting routine used 128
coefficients to separate the data, each of which was then passed through a digital band
pass-filter designed to allow passage of frequencies between 30-40 Hz. The values of
each of the 128 coefficients were then summated to yield the total gamma waveform that
could then be used to calculate the gamma power in both the early and late time frame.
Statistical analysis was performed to determine changes between baseline values and post
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treatment values. In this study our hypothesis was that we would see statistically lower
gamma responses post treatment, indicative of less attentional resources being dedicated
to the analysis of drug related stimuli.
Long-range gamma coherence is representative of interbrain connectivity during
the recognition and analysis of a given stimulus. EEG coherence analysis is a technique
that investigates the pair-wise correlations of power spectra obtained from different
electrodes. It measures the functional interaction between cortical areas in different
frequency bands, with high level of coherence between two EEG signals indicating coactivation of neuronal populations. Coherence was calculated for the 30-45 Hz by
passing the raw EEG data to BESA and using its own coherence toolboxes. This process
resulted in a bitmap image, which was exported to a custom MatLab algorithm to give a
quantitative average coherence value over a 100 ms X 5 Hz window. In this study we
expected to see statistically higher coherence values post neurofeedback training.
In this pilot study we selected ten drug addicted patients, (two females, eight
males) mean age, 44.6 ±8.3, range 35-54 years, 70% Afro-Americans), to participate in
the study. All patients were carefully screened for inclusion in the experiment, informed
of all procedures and protocols, and signed the consent form approved by the University
of Louisville’s IRB. These patients then underwent a baseline cue reactivity test, 12
neurofeedback sessions, at least 2 MI sessions, and a post treatment cue reactivity test.
The neurofeedback protocol consisted of simultaneously increasing SMR frequencies
(12-15Hz) at the C3 recording sight and decreasing Theta frequencies (4-7Hz) at the F3
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recording site. Data from the two cue reactivity tests were segmented and analyzed using
the protocols outlined above.
As a result of this study it is the conclusion of the authors that the gamma band
indices developed through this research were sufficiently sensitive to changes in the EEG
pattern to be indicative of improvement over the course of neurofeedback treatment. As
was predicted prior to onset of the study, subjects did show decreases in gamma power to
both target and non-target stimuli post neurofeedback, and increases in long-range
coherence were also seen.
Despite the positive results of this study there are still several limitations, which
need to be addressed. The first major complication is that there was no control group of
demographically matched non-addicted patients and our test group was small. The no
control group implies that while we know the gamma powers decreased and coherence
values increased in addicted patients, we are unable to compare these differences to prepost NFB differences seen in a non-addicted patient. In a similar fashion our data may be
skewed by the small sample size used in this pilot study. Through careful analysis of the
gamma power results it was possible to highlight topographical difference that were
trending towards significance which may be found if a larger data pool was used.
Another potential setback of this study is the fact that two different treatment
modalities were employed simultaneously, namely motivational interviewing and
neurofeedback. As a result of this we have no way of isolating the effects seen in this
study as being the effect of either modality. While motivational interviewing was used as
a method to get patients actively involved in the study and retain them, it is possible that
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patients received some benefit through the process that could manifest itself in alterations
of the gamma waveform.
The third major limitation of this study comes from the selection of electrodes.
We used a 128-electrode net to collect the data, yet only eight channels were analyzed.
These eight channels were selected as points of different brain regions to give a
widespread view of the brain and to allow for comparisons between medial and lateral as
well as frontal and parietal regions. However, by only taking a single electrode we fail to
capture large-scale regional comparisons, which may yield more information about longrange coherence in the brain. BESA is capable of creating montages which calculate the
average responses of a given brain region which could then be used to calculate
coherence and gamma power, allowing the same modality to be used on a more
comprehensive data set.
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VII. Future Work and Application:

This protocol allows for a large deal of continuation research. As it applies
specifically to cocaine related drug addiction, further studies to collect more study
subjects, and also the collection of a control group would be greatly beneficial. Also an
additional follow-up time point may be added to the research to determine how long
beneficial results remain after neurofeedback treatment. This data is currently being
collected and analyzed by members of the research lab responsible for the data collected
here. Also, all data presented here is representative of drug related cues, not neutral
related cues. While it has been shown previously that drug-addicted patients show
increased responses to drug related cues as compared to neutral cues, it may be
informative to compare changes in both categories after neurofeedback as well.
Additional future work includes expanding this methodology to other areas of
research in the neurofeedback field. The methodologies laid out here are applicable to a
wide range of psychiatric disorders, including ADHD, schizophrenia and posttraumatic
stress disorder (PTSD) with minimal modification. Again research is already being
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collected here at the University of Louisville to investigate the effects of PTSD on the
gamma band, an area of increasing interest given the large number of returning veterans
who may suffer from PTSD. Additionally a study is already underway to study the effects
of neurofeedback specifically targeted to provide real time audio and visual feedback
based upon the level of gamma activity recorded from the subject. In this study we have
already recruited 5 addicts and 5 controls as a pilot data set that we expect to publish
results from within the year.
These techniques are also not limited to the gamma frequency band. The
waveleting techniques outlined in this paper could be easily modified to isolate
frequencies of the alpha, beta, theta or any other sub-band of the EEG waveform. In
addition, the coherence calculations made here may be used to analyze a wide range of
brain frequencies. The main limitation in the analysis of coherence is the BESA
program. BESA has set ranges that may be used to define frequencies for coherence
analysis, and these frequencies may not go sufficiently low for analysis of the low
frequency bands such as theta and beta. However in this case it should be possible to
devise additional custom MatLab programs, which could take the filtered data set and
calculate coherence manually. The versatility of the methodologies outlined in this thesis
makes them applicable in several areas of EEG analysis with very little change and allow
for the quick and repeatable creation of quantifiable data sets.
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Appendix 1: MatLab Codes:
i) Main Runtime
clear all
close all
clc
format long
Maximum_Coorelation = 1; % you have to change this number based on the capture
image
Scale = [0:Maximum_Coorelation./510:Maximum_Coorelation];
load data_file Color_Map_Matrix
for kkk=1:64
if kkk<10
File_Name=['PR_00' num2str(kkk) '.bmp'];
elseif kkk>=10 && kkk<100
File_Name=['PR_0' num2str(kkk) '.bmp'];
else
File_Name=['PR_' num2str(kkk) '.bmp'];
end
Test_Image=coherence_image(File_Name);%generate individual electrode images
Correlation_Matrix=zeros(1,8); %Initialize Matrix
for j=1:8
Average_Correlation=zeros(1,848);
Window=window_maker(Test_Image(:,:,:,j)); %Create Windows for the given image
[Row_Index Col_Index Layer Image]=size(Window(:,:,:,1));
%Calculate Coherence
for i=1:848
Sum_Cor = 0;
Counter = 0;
for a=1:Row_Index
for b=1:Col_Index
R = double(Window(a,b,1,i));
G = double(Window(a,b,2,i));
B = double(Window(a,b,3,i));
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distance_v = ((R - Color_Map_Matrix(:,1)).^2 + (G Color_Map_Matrix(:,2)).^2
+ (B – Color_Map_Matrix(:,3)).^2).^(0.5);
[min_dis pos_value] = min(distance_v);
Coorelation_value = Scale(pos_value);
Sum_Cor = Sum_Cor + Coorelation_value;
Counter = Counter + 1;
clear distance_v
end
end
Average_Correlation(1,i) = Sum_Cor./Counter;
end
Correlation_Matrix(1,j)= max(Average_Correlation);%find highest value of
window
end
%
%

Correlation_Matrix; %display matrix
fprintf('Be sure to remember one value is the reference and should be ignored\n')

Sxls1=['B' num2str(kkk+1) ':I' num2str(kkk+1)];
xlswrite('All_Results.xls',Correlation_Matrix,Sxls1)
kkk
end
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ii.) Image Segmentation Function
function[Test_Image]=coherence_image(File_Name)
%coherence image splitter
%Tim Horrell
%February 22, 2010
%Given a 2,4 image array, this program will produce eight pictures which
%can then be individually tested
Input_Image=imread([cd '\Images\' File_Name]);
Test_Image=zeros(394,295,3,8);
for i=0:3
for layer=1:3
for j=1:394
for k=1:295
Test_Image(j,k,layer,i+1)=Input_Image(20+j,(24+318*i)+k,layer);
end
end
end
end
% figure
% subplot(2,2,1)
% imshow(Test_Image(:,:,:,1))
% subplot(2,2,2)
% imshow(Test_Image(:,:,:,2))
% subplot(2,2,3)
% imshow(Test_Image(:,:,:,3))
% subplot(2,2,4)
% imshow(Test_Image(:,:,:,4))
for i=0:3
for layer=1:3
for j=1:394
for k=1:295
Test_Image(j,k,layer,i+5)=Input_Image(455+j,(24+318*i)+k,
layer);
end
end
end
end
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iii.) Window Making Function
function [Window]=window_maker(Input_Image)
%coherence image splitter
%Tim Horrell
%February 22, 2010
%Given a input image array, this program will produce a specified set of window
%images which can then be individually tested
Window=zeros(130,30,3,848);
counter=1;
for v_shift=1:5:261
for h_shift=121:2:151
for layer = 1:3
for i= 1:130
for j= 1:30
Window(i,j,layer,
counter)=Input_Image(v_shift+i,j+h_shift,layer);
end
end
end
counter=counter+1;
end
end
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Appendix II: Data Tables
TABLE II
T-TEST OF THE DIFFERENCES BETWEEN PRE AND POST NFB EARLY
GAMMA COHERENCE TO TARGET DRUGS
One-Sample Test
Test Value = 0
Mean
t

df

Sig. (2-tailed)

Difference

F7_F1

3.591

6

.011

.223573

F7_F2

.594

6

.574

.027164

F7_F8

.536

6

.611

.023116

F7_P7

1.050

6

.334

.034787

F7_P3

.175

6

.867

.003330

F7_P4

2.045

6

.087

.066962

F7_P8

.954

6

.377

.051838

F1_F2

-.271

6

.795

-.011503

F1_F8

.930

6

.388

.040995

F1_P7

.771

6

.470

.039371

F1_P3

.384

6

.714

.022367

F1_P4

3.051

6

.022

.145110

F1_P8

3.301

6

.016

.123250

F2_F8

-.531

6

.614

-.074125

F2_P7

.234

6

.823

.007712

F2_P3

.674

6

.525

.035374

F2_P4

.898

6

.404

.046554

F2_P8

1.015

6

.349

.048434

F8_P7

-.150

6

.885

-.005207

F8_P3

-.275

6

.792

-.010297

F8_P4

.294

6

.779

.011803

F8_P8

1.423

6

.205

.034904

P7_P3

-.120

6

.909

-.012001

P7_P4

.697

6

.512

.027238

P7_P8

-.115

6

.912

-.007189

P3_P4

-1.455

6

.196

-.036053

P3_P8

.267

6

.798

.014323

P4_P8

.717

6

.501

.053361
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TABLE III
T-TEST OF THE DIFFERECNE BETWEEN PREA AND POST NFB EARLY
GAMMA COHERENCE TO NON-TARGET DRUGS
One-Sample Test
Test Value = 0
Mean
t

df

Sig. (2-tailed)

Difference

F7_F1

2.613

7

.035

.310625

F7_F2

.620

7

.555

.041250

F7_F8

.964

7

.367

.043250

F7_P7

1.646

7

.144

.146625

F7_P3

1.267

7

.246

.116500

F7_P4

2.197

7

.064

.099375

F7_P8

1.070

7

.320

.105625

F1_F2

.494

7

.637

.047875

F1_F8

.990

7

.355

.060875

F1_P7

1.160

7

.284

.113625

F1_P3

1.285

7

.240

.102750

F1_P4

1.990

7

.087

.125625

F1_P8

1.622

7

.149

.147500

F2_F8

1.041

7

.332

.134500

F2_P7

.307

7

.768

.020125

F2_P3

.837

7

.430

.039875

F2_P4

1.260

7

.248

.139500

F2_P8

1.621

7

.149

.108375

F8_P7

.534

7

.610

.031125

F8_P3

.701

7

.506

.029875

F8_P4

1.412

7

.201

.129750

F8_P8

1.855

7

.106

.079375

P7_P3

-.463

7

.657

-.034875

P7_P4

1.355

7

.218

.059375

P7_P8

1.479

7

.183

.147375

P3_P4

.971

7

.364

.032875

P3_P8

.823

7

.437

.098500

P4_P8

1.217

7

.263

.085250
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TABLE VI
T-TEST OF THE DIFFERECNE BETWEEN PREA AND POST NFB LATE GAMMA
COHERENCE TO TARGET DRUGS
One-Sample Test
Test Value = 0
Mean
t

df

Sig. (2-tailed)

Difference

F7_F1

5.393

6

.002

.232429

F7_F2

.222

6

.832

.010286

F7_F8

.723

6

.497

.021286

F7_P7

1.007

6

.353

.046286

F7_P3

.664

6

.531

.012714

F7_P4

3.165

6

.019

.091286

F7_P8

2.556

6

.043

.091714

F1_F2

-.545

6

.605

-.021429

F1_F8

.748

6

.483

.029143

F1_P7

.940

6

.383

.053429

F1_P3

.345

6

.742

.018143

F1_P4

5.076

6

.002

.173000

F1_P8

2.671

6

.037

.127571

F2_F8

-.351

6

.738

-.047857

F2_P7

-.487

6

.644

-.018714

F2_P3

.801

6

.454

.028429

F2_P4

1.057

6

.331

.025429

F2_P8

2.252

6

.065

.072571

F8_P7

-.997

6

.357

-.025857

F8_P3

.298

6

.775

.006857

F8_P4

-.472

6

.654

-.011286

F8_P8

1.108

6

.310

.022000

P7_P3

-.165

6

.875

-.014143

P7_P4

.263

6

.801

.013857

P7_P8

.783

6

.463

.040286

P3_P4

-.464

6

.659

-.019143

P3_P8

.389

6

.711

.014429

P4_P8

.264

6

.801

.015286

68

TABLE V
T-TEST OF THE DIFFERECNE BETWEEN PREA AND POST NFB LATE GAMMA
COHERENCE TO NON-TARGET DRUGS
One-Sample Test
Test Value = 0
Mean
t

df

Sig. (2-tailed)

Difference

F7_F1

2.705

7

.030

.271625

F7_F2

.459

7

.660

.021500

F7_F8

.889

7

.404

.082750

F7_P7

1.587

7

.157

.113750

F7_P3

1.223

7

.261

.102125

F7_P4

2.178

7

.066

.142750

F7_P8

1.323

7

.227

.090750

F1_F2

.439

7

.674

.045625

F1_F8

1.259

7

.248

.114500

F1_P7

.971

7

.364

.089375

F1_P3

1.406

7

.203

.098250

F1_P4

1.573

7

.160

.137250

F1_P8

2.202

7

.064

.179750

F2_F8

.839

7

.429

.112750

F2_P7

.866

7

.415

.063875

F2_P3

.773

7

.465

.053375

F2_P4

1.032

7

.336

.120000

F2_P8

1.674

7

.138

.132375

F8_P7

1.245

7

.253

.112375

F8_P3

.228

7

.826

.009875

F8_P4

1.117

7

.301

.107375

F8_P8

1.848

7

.107

.106625

P7_P3

-.748

7

.479

-.046750

P7_P4

.713

7

.499

.042750

P7_P8

1.631

7

.147

.150000

P3_P4

.886

7

.405

.074125

P3_P8

1.419

7

.199

.102375

P4_P8

1.436

7

.194

.079750
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TABLE VI
Compiled coherence results of the early gamma window when presented with a target cue pre NFB.

TABLE VII
Compiled coherence results of the early gamma window when presented with a target cue post NFB
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TABLE VIII
Compiled coherence results of the early gamma window when presented with a non-target cue pre NFB.

TABLE IX
Compiled coherence results of the early gamma window when presented with a non-target cue post NFB
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TABLE X
Compiled coherence results of the late gamma window when presented with a target cue pre NFB.

TABLE XI
Compiled coherence results of the late gamma window when presented with a target cue post NFB
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TABLE XII
Compiled coherence results of the late gamma window when presented with a non-target cue pre NFB.

TABLE XIII
Compiled coherence results of the late gamma window when presented with a non-target cue post NFB
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Appendix III: Additional Cue Reactivity Images
i.) Neutral Household Images:
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ii.) Neutral Nature Images:

76

77

iii.) Drug Images:
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